XAIRBeyond Air, Inc.
- GlobeNewswire
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closing Beyond Air eligible to receive up to $32.5 million in development and commercial milestone payments ...
- GlobeNewswire
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement for second-generation LungFit PH system under FDA review; ...
- GlobeNewswire
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
GARDEN CITY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on ...
- GlobeNewswire
Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
GARDEN CITY, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on ...
- GlobeNewswire
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026 The Company is transitioning its year-end from March 31st to ...
- GlobeNewswire
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on ...
- GlobeNewswire
Beyond Air, Inc. Urges Stockholders to Vote "FOR" All Proposals Ahead of the Upcoming Special Meeting
Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information is included ...
- GlobeNewswire
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve ...
- SEC
PRE 14A Form - Other preliminary proxy statements - Beyond Air, Inc. (0001641631) (Filer)
Other preliminary proxy statements ...
- GlobeNewswire
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
Updated AACR poster data show continued survival follow-up in heavily pre‑treated patients following a single intratumoral UNO injection Received US patent allowance covering proprietary gas delivery technology for UNO ...
- GlobeNewswire
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve ...
- GlobeNewswire
Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)
GARDEN CITY, N.Y., April 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve ...
- GlobeNewswire
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of ...
- GlobeNewswire
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of ...
- GlobeNewswire
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of ...
- Earnings Call Transcripts
Beyond Air, Inc. Third Quarter 2026 Earnings Call - BEYOND AIR INC
Good morning, and welcome, everyone, to Beyond Air Financial Results Call for the Fiscal Quarter ended December 31, 2025. At this time, all participants are in listen-only mode. A question-and-answer session will follow ...
- GlobeNewswire
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable ...
- Earnings Call Transcripts
Beyond Air - Noble Capital Markets Virtual Equity Conference - BEYOND AIR INC
I'm Robert LaBoyer, Senior Biotechnology Analyst at Noble Capital Markets. Our next presenting company is Beyond Air, a company developing nitric oxide therapies for therapeutic uses. With us to present is CEO and Chairm ...
- GlobeNewswire
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026
GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and ...
- GlobeNewswire
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of ...
- GlobeNewswire
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of ...
- Analyst Upgrades
D. Boral Capital Maintains Buy on Beyond Air, Maintains $11 Price Target
D. Boral Capital analyst Jason Kolbert maintains Beyond Air with a Buy and maintains $11 price target. ...
- Earnings Call Transcripts
BEYOND AIR FIRESIDE CHAT @ LYTHAM PARTNERS 2026 INVESTOR HEALTHCARE SUMMIT - BEYOND AIR INC
Hello, and welcome to the Beyond Air Fireside Chat. My name is Roger Weiss, and I'm a Vice President here at Lithium Partners. Today, I'll be moderating a Q&A discussion with Steve Lissy, CEO and Chairman of the board at ...
- GlobeNewswire
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
GARDEN CITY, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of ...
- GlobeNewswire
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying ...